# Novo Nordisk A/S: Phase 1 study closed enrollment, 29 enrolled (Fatty Liver Disease)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat |
| NCT ID | NCT07214870 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Fatty Liver Disease |
| Intervention types | drug |
| Target enrollment | 29 |
| Site countries | Canada |
| Posted | 2025-10-09 |
| Planned start | 2025-10-08 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-13 |
| Last update posted | 2026-10-13 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07214870). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.